Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04442646 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of "Asthma School" in Disease Management

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Nov 15, 2025 to Dec 15, 2026
    • Study completion date: Dec 1, 2025 to Dec 15, 2026
    v8
  2. Primary completion date: Nov 15, 2024 to Nov 15, 2025
    • Study completion date: Dec 1, 2024 to Dec 1, 2025
    v7
  3. Primary completion date: Aug 15, 2024 to Nov 15, 2024
    • Study completion date: Sep 1, 2024 to Dec 1, 2024
    v6
  4. Primary completion date: Dec 1, 2023 to Aug 15, 2024
    • Study completion date: Dec 1, 2023 to Sep 1, 2024
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Apr 1, 2021 to Dec 1, 2023
    • Study completion date: Apr 1, 2022 to Dec 1, 2023
    v3
  2. Secondary endpoints revised (5)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough. The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections. The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators. Patients affected by severe asthma (\~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy.The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals
Trial Details
NCT Number NCT04442646
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Conditions
(from sponsor)		 Asthma
Related terms Asthma
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov